Evidence-Based Complementary and Alternative Medicine / 2020 / Article / Tab 2 / Review Article
The Effectiveness of Acupuncture in Management of Functional Constipation: A Systematic Review and Meta-Analysis Table 2 Characteristics of included studies.
Author Study sites n Diagnostic criteria Participants Participants’ age (years, M ± SD) Disease course (M ± SD) Duration Outcomes Acupuncture vs sham electroacupuncture Da et al. [26 ] 1 67 Rome III Treatment: 34 37.94 ± 18.06 139.59 ± 112.68 mos 8 weeks ①③⑥ Control: 33 37.00 ± 17.89 106.21 ± 91.98 mos Lee et al. [27 ] 1 29 Rome III Treatment: 14 49.6 ± 12.7 Not reported 4 weeks ①②⑥ Control: 15 50.0 ± 10.5 Not reported Liu et al. [28 ] 15 1075 Rome III Treatment: 536 47.01 ± 16.5 130.8 ± 122.6 mos 8 weeks ①②③⑤⑥ Control: 539 47.33 ± 15.8 132.7 ± 127.0 mos Wu [29 ] 1 120 Rome III Treatment: 60 49 ± 34.5 68.5 ± 94.5 mos 8 weeks ②③⑥ Control: 60 52.63 ± 12.9 101 ± 102.2 mos Xue et al. [30 ] 1 96 Rome III Treatment: 48 48.85 ± 13.30 7.65 ± 6.48 yrs 4 weeks ④⑥ Control: 48 45.25 ± 11.28 8.48 ± 5.76 yrs Acupuncture vs polyethylene glycol Chen [31 ] 1 61 Rome III Treatment: 30 48.80 ± 8.18 5.06 ± 3.66 mos 4 weeks ⑥ Control: 31 48.58 ± 8.14 4.94 ± 3.68 mos Mao [32 ] 1 62 Rome III Treatment: 30 74.5 1 mos 2 weeks ⑤⑥ Control: 32 73 1 mos Ou [33 ] 1 170 Rome III Treatment: 84 48.03 ± 17.19 24.52 ± 11.32 mos 4 weeks ⑤⑥ Control: 86 46.64 ± 15.71 23.5 ± 10.36 mos Acupuncture vs mosapride Ding et al. [34 ] 1 63 Rome III Treatment: 33 34.83 ± 11.76 5.71 ± 2.54 yrs 4 weeks ② Control: 30 Lian et al. [35 ] 1 63 Rome III Treatment: 33 26.85 ± 8.27 3.44 ± 2.56 yrs 4 weeks ② Control: 30 27.60 ± 7.86 2.92 ± 2.24 yrs Wang et al. [36 ] 1 68 Rome III Treatment: 34 47.8 ± 10.1 7. 6 ± 6.4 yrs 4 weeks ① Control: 34 46. 6 ± 11. 0 8.1 ± 5.9 yrs Wang [37 ] 1 54 Rome III Treatment: 37 28.08 ± 13.42 95.43 ± 103.03 mos 4 weeks ⑤ Control: 17 27.59 ± 9.70 92.00 ± 78.48 mos Acupuncture vs prucalopride Dai [38 ] 1 60 Rome III Treatment: 30 40.48 ± 2.96 110.76 ± 17.4 mos 8 weeks ①②③⑤ Control: 30 42.80 ± 3.92 150.48 ± 30.84 mos Mao [39 , 40 ] 1 56 Rome III Treatment: 28 44.85 ± 7.71 3.78 ± 2.12 yrs 8 weeks ①②③ Control: 28 46.95 ± 9.83 3.88 ± 2.36 yrs Song [41 ] 1 39 Rome III Treatment: 20 51.40 ± 12.90 Not reported 8 weeks ①②③⑤ Control: 19 49.16 ± 12.31 Not reported Wang et al. [42 ] 1 60 Rome III Treatment: 30 46 ± 7 4.52 ± 2.36 yrs 4 weeks ①② Control: 30 47 ± 8 4.64 ± 2.65 yrs Wang [43 ] 1 38 Rome III Treatment: 19 41.53 ± 16.15 76.68 ± 7.75 mos 8 weeks ①②③⑤ Control: 19 35.29 ± 13.26 76 ± 4.93 mos Acupuncture vs cisapride Zhou et al. [44 ] 1 60 The guidelines for clinical research Treatment: 30 37. 36 ± 10. 32 2. 54 ± 1. 63 yrs 4 weeks ⑤ Control: 30 39. 58 ± 11. 63 2. 72 ± 1. 76 yrs Acupuncture vs lactulose Jin [45 ] 1 37 Rome III Treatment: 22 39.14 ± 14.45 115.18 ± 108.08 mos 4 weeks ④ Control: 15 45.13 ± 17.09 157.4 ± 142.24 mos Liu et al. [46 ] 1 60 Rome III Treatment: 30 53. 13 ± 9. 65 3.70 ± 2. 54 yrs 2 weeks ①⑤ Control: 30 52.76 ± 8.87 3.96 ± 2.68 yrs Ruan et al. [47 ] 1 45 Rome III Treatment: 21 68 ± 9 17.90 ± 9.77 mos 3 weeks ②③ Control: 24 69 ± 8 16.92 ± 10.04 mos Shi [48 ] 1 60 Rome III Treatment: 30 64.87 ± 4.208 5.27 ± 3.51 yrs 4 weeks ②④⑥ Control: 30 66.27 ± 3.513 5.5 ± 3.94 yrs Acupuncture vs sham acupuncture vs lactulose Peng et al. [49 , 50 ] 3 128 Rome III Treatment: 64 53 ± 13 125.1 ± 128.6 mos 4 weeks ④⑥ Control A: 33 52 ± 17 118 ± 105.8 mos Control B: 31 59 ± 12 97.8 ± 123 mos Wang et al. [51 ] 1 95 Rome III Treatment: 48 48.8 ± 13.3 7.65 ± 6.48 yrs 4 weeks ④⑥ Control A: 24 40.8 ± 10.0 9.46 ± 5.89 yrs Control B: 23 44.6 ± 15.2 7.65 ± 5.65 yrs Wu et al. [52 ] 5 475 Rome III Treatment: 228 45.88 ± 16.85 110.84 ± 99.85 mos 4 weeks ④⑥ Control A: 112 46.25 ± 16.81 109.25 ± 100.70 mos Control B: 115 44.12 ± 17.48 111.04 ± 110.15 mos Acupuncture vs mosapride vs mosapride & sham electroacupuncture Xu [53 ] 1 90 Rome III Treatment: 30 35.26 ± 19.07 8.88 yrs 4 weeks ②③⑤⑥ Control A: 30 35.42 ± 15.28 8.71 yrs Control B: 30 36.00 ± 17.20 8.83 yrs Low intensity acupuncture vs high intensity acupuncture vs mosapride Wu et al. [54 ] 3 190 Rome III Treatment A: 58 34.00 ± 15.62 70.44 ± 85.53 mos 4 weeks ⑥ Treatment B: 65 37.20 ± 18.19 86.29 ± 104.06 mos Control: 67 43.60 ± 17.90 68.09 ± 74.13 mos Shu-mu vs He vs Shu-mu-he vs mosapride Wu et al. [55 ] 1 104 Rome III Treatment A: 19 61 (16) 130 mos 4 weeks ⑥ Treatment B: 34 53 ± 12 123 mos Treatment C: 26 56 ± 9 217.35 mos Control: 25 55 ± 11 130 mos
Notes: M ± SD, the mean ± standard deviation; mos, months; yrs, years; ① complete spontaneous bowel movement (CSBM); ② Bristol Stool Form Scale (BSFS); ③ responder rate; ④ constipation symptoms scores (CSS); ⑤ Patient Assessment Of Constipation Quality Of Life (PAC-QOL) questionnaire; ⑥ safety evaluation.
